ARTICLE | Clinical News
Opicapone: Phase III data
March 30, 2015 7:00 AM UTC
The double-blind, European Phase III BIPARK-1 trial in 660 patients with idiopathic PD and motor fluctuations showed that once-daily 50 mg opicapone as an add-on to levodopa significantly reduced “off...